A map released by the Global Initiative on Sharing All Influenza Data (GISAID) shows that 21 states in the United States are reporting COVID-19 variant NB.1.8.1 as of Thursday afternoon.

The most recent estimate from the Centers for Disease Control and Prevention suggests that between June 8 and June 21, the NB.1.8.1 variant now makes up 43 percent of COVID-19 cases in the United States, making it now the dominant strain.

Separately, the CDC says that across the United States, COVID-19 levels are "currently very low."

Outside the United States, Chinese health officials said in June that the NB.1.8.1 was driving a wave of infections across the country. And Chinese doctors at Peking University last month predicted a peak of nationwide COVID-19 cases in July, also stating that it may become the next dominant global strain, with symptoms including a sharp sore throat, fever, runny nose, vomiting, and diarrhea.

Due to the Chinese Communist Party's history of covering up information and publishing unreliable data, including data on COVID-19 infections and deaths, information provided by local doctors and health workers could provide more context about the situation on the ground in China.

The World Health Organization (WHO) has designated NB.1.8.1 as a "variant under monitoring" and considers the public health risk low at the global level. Current vaccines are expected to remain effective.

Previously, WHO said some western Pacific countries have reported increases in COVID-19 cases and hospitalizations, but there's nothing so far to suggest that the disease associated with the new variant is more severe than other variants.

NB.1.8.1 has been dubbed the "razor throat" or "razor blade throat" variant in media reports, including in India, the UK, China, and by The Associated Press. Several Chinese doctors told The Epoch Times in May that their patients had reported the symptom.

Separately, the WHO announced that the XFG strain is now a "variant under monitoring" in a report released in late June. XFG is estimated to make up around 14 percent of cases in the United States, and GISAID isn't tracking the variant so far.